$HGEN when looking at the gilead remdesivir trial, the treatment had a 2.8% mortality rate in the cohort of 500 patients who received the drug, this was better than the control where placebo group had a mortality rate slightly over 3%. We also know that within the group that received remdesivir the drug was barely better than placebo in more severe cases with a hazard ratio of 1.08. From the latest humanigen release we see an improvement on remdesivir / SOC that is predicted to hit 37%. It’s possible we see the mortality rate for those taking Lenz go under 2% when the numbers are released in the next interim analysis.
  • 4